Loading
Medifast Inc Stock: price and insider trades · United States
1 insider bought €1.2M of shares over the last 90 days, the latest filed 28 Aug 2026.
Medifast Inc: what insiders have been doing
Medifast Inc, classified in the Healthcare & Pharma sector, is a listed company based in Baltimore, United States, founded in 1980. Its insiders report their share dealings to SEC (Form 4). The last twelve months, up to 18 October 2026, brought 16 filings signed by 6 insiders.
Open-market activity splits into 8 purchases totalling €1.2M and 2 sales totalling €199k; 1 insider sit on the buying side and 1 insider on the selling side. The net balance comes to €1.0M on the buying side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. The buyers include 1 senior executive. At €441k, the purchase published on 28 August 2026 by Kiai Parsa is the largest of the period (0.37% of market cap).
With 16 filings in twelve months, the company is quieter than the median of 19 filings across the 5,812 companies we follow on the same exchange. Our records for Medifast Inc go back to 2016, with 39 purchases and 16 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts revenue at 385.8 m USD and net income at -18.7 m USD.
The last insider purchase was made public on 28 August 2026, 51 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Cytosorbents Corp also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
146
Thresholds
n/a
Buy Volume
€2M
39 ops. · all time
Sell Volume
€3M
16 ops. · all time
Who traded when
BuySaleParsa Kiai8 buys
Daniel R. Chard1 buy2 sales
Since the insiders bought
- -2.4%Entry US$12.14 · Close 14 Oct 2026 US$11.85
- -22.1%Entry US$14.17 · Close at T+365 US$11.04
- -70.3%Entry US$65.40 · Close at T+365 US$19.43
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 18,134 of 24,148 companies
34.6
score / 100
Value29
Quality40
FCF yld0.9%
Earn yld-14%
EV/EBITDA·
ROE-12%
Gross mgn71%
Net mgn-4.8%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.67
Analyst consensus
1 analysts3.00/5
US$12.00Target US$12.00(+3%)US$12.00
Income statement
RevenueUS$385.8M
Gross profitUS$275.2M71% margin
EBITDAUS$29k0% margin
Net income-US$18.7M-8.1% margin
Valuation
PER (forward)-41.7x
P/Book0.6x
Beta0.70
Balance sheet & cash
Market capUS$130.5M
Total debtUS$10.7M
Free Cash FlowUS$1.2M
Debt / Equity14%
Profitability & ownership
ROE-12.4%
ROA-4.6%
% insiders4.3%
% institutions75.1%
Last declaration on 30 September 2026
Declarations146 total
9,545 shares@ US$11.97880.088% mcap5.4% of flowCommon StockSEC:0001628280-26-064063:0
9,544 shares@ US$11.730.086% mcap5.3% of flowCommon StockSEC:0001628280-26-064063:1
9,544 shares@ US$11.730.086% mcap6.0% of flowCommonSEC144:0001959173-26-007140
9,545 shares@ US$11.97880.087% mcap6.5% of flowCommonSEC144:0001959173-26-007123
41,975 shares@ US$12.26320.37% mcap36.1% of flowCommon StockSEC:0001213900-26-094862:0
Canonical exit: 24 Nov 2026 (T+90)
1,175 shares@ US$12.26320.010% mcap1.0% of flowCommon StockSEC:0001213900-26-094862:1
Canonical exit: 24 Nov 2026 (T+90)
4,211 shares@ US$11.99960.036% mcap3.5% of flowCommon StockSEC:0001213900-26-093824:0
Canonical exit: 22 Nov 2026 (T+90)
118 shares@ US$11.99960.0010% mcap0.1% of flowCommon StockSEC:0001213900-26-093824:1
Canonical exit: 22 Nov 2026 (T+90)
799 shares@ US$11.65760.0067% mcap0.7% of flowCommon StockSEC:0001213900-26-092479:1
Canonical exit: 17 Nov 2026 (T+90)
41,975 shares@ US$11.60370.35% mcap34.1% of flowCommon StockSEC:0001213900-26-092479:2
Canonical exit: 18 Nov 2026 (T+90)
1,175 shares@ US$11.60370.0098% mcap1.0% of flowCommon StockSEC:0001213900-26-092479:3
Canonical exit: 18 Nov 2026 (T+90)
28,538 shares@ US$11.65760.24% mcap23.5% of flowCommon StockSEC:0001213900-26-092479:0
Canonical exit: 17 Nov 2026 (T+90)
11,680 shares0Common StockSEC:0001628280-26-038974:0
198 shares@ US$9.6211.2% of flowCommon StockSEC:0001628280-26-021797:0
918 shares@ US$9.628.6% of flowCommon StockSEC:0001628280-26-021796:0
7,075 shares@ US$9.624.1% of flowCommon StockSEC:0001628280-26-021795:0
11,168 shares0Common StockSEC:0001628280-25-033185:0
11,168 shares0Common StockSEC:0001628280-25-033184:0
11,168 shares0Common StockSEC:0001628280-25-033183:0
11,168 shares0Common StockSEC:0001628280-25-033182:0
11,167.542 shares0Common StockSEC:0001628280-25-033181:0
381 shares@ US$13.130.3% of flowCommon StockSEC:0001628280-25-031936:0
Canonical exit: 11 Sept 2025 (T+90)
124,953 shares0Common StockSEC:0001628280-25-015270:0
24,161 shares0Common StockSEC:0001628280-25-015274:0
7,671 shares0Common StockSEC:0001628280-25-015272:0
25 of 146 declarations
About Medifast Inc
Medifast Inc. (NYSE: MED) is a U.S.-listed health and wellness company headquartered in Baltimore, Maryland, United States. Its roots go back to 1980, and over time the business evolved from a weight-management specialist into a broader metabolic-health platform. In its latest public disclosures, Medifast describes itself as a science-backed, coach-guided lifestyle company built around structured nutrition, behavior change, and proprietary products. The company also operates a modern FDA-approved manufacturing facility in Owings Mills, Maryland, which is important operationally because it gives Medifast direct control over part of its supply chain and product quality.
The core commercial engine is the OPTAVIA® brand, sold through a network of independent coaches who provide one-on-one support and accountability to clients. This model is a key differentiator versus traditional packaged-food or supplement companies: Medifast is not just selling meal replacements, it is selling an integrated system that combines product, coaching, and community. Its main product lines currently include Essential Fuelings, OPTAVIA ASCEND, and OPTAVIA ACTIVE, alongside newer protein-forward offerings designed to address evolving consumer needs. In January 2025, the company introduced OPTAVIA ASCEND, a high-protein line aimed at GLP-1 users and people trying to keep weight off. Later in 2025, Medifast announced a strategic shift toward metabolic health and launched its Metabolic Synchronization™ framework.
Read moreShow less
From a competitive standpoint, Medifast operates in a crowded and fast-changing market. It faces competition from diet and lifestyle programs, digital coaching platforms, functional nutrition brands, and increasingly from the secular impact of GLP-1 obesity medications. Medifast’s advantage lies in its long operating history, its coached model, and the recurring nature of its client engagement. At the same time, the company has acknowledged pressure on its coach network and recent volume weakness, which remain central investor concerns.
Geographically, Medifast remains primarily U.S.-focused, although it has some international entities and limited overseas activity. On the stock market, the company trades on the NYSE under ticker MED, in the United States. Recent headline developments include its 2025 financial results, which showed revenue of $385.8 million and a net loss for the year, while the balance sheet remained strong with substantial cash and no debt. For French-speaking investors, Medifast is best viewed as a consumer-health transition story: an established brand with a differentiated distribution model, but one that is actively repositioning itself to capture a broader metabolic-health opportunity.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
